This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sun, A.
Right arrow Articles by Tian, Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sun, A.
Right arrow Articles by Tian, Z.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, February 2006, p. 227-234, Vol. 13, No. 2
1071-412X/06/$08.00+0     doi:10.1128/CVI.13.2.227-234.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Human Interleukin-15 Improves Engraftment of Human T Cells in NOD-SCID Mice

Anyuan Sun,1 Haiming Wei,1 Rui Sun,1,2 Weihua Xiao,1 Yongguang Yang,3 and Zhigang Tian1,2*

School of Life Sciences, University of Science and Technology of China, Hefei 230027,1 School of Pharmaceutical Sciences, Shandong University, Jinan 250021, China,2 Transplantation Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 021293

Received 8 August 2005/ Returned for modification 15 September 2005/ Accepted 23 November 2005


arrow
ABSTRACT
 
Human nonobese diabetic-severe combined immune deficiency (NOD-SCID) mouse chimeras have been widely used as an in vivo model to assess human immune function. However, only a small fraction of transferred human T lymphocytes can be detected in human peripheral blood lymphocyte (huPBL)-NOD-SCID chimeras. To improve the reconstitution of human T lymphocytes in NOD-SCID mice, the use of recombinant human interleukin-15 (rhIL-15) as a stimulator of human lymphocytes was explored. Administration of rhIL-15 after transplantation of huPBLs into NOD-SCID mice increased reconstitution of human T lymphocytes in a dose-dependent manner, with an optimal dosage of 1 µg/mouse. The number of human T lymphocytes (HLA-ABC+ CD3+) in the lymphoid organs or tissue of rhIL-15-treated huPBL-NOD-SCID mice increased 11- to 80-fold, and phytohemagglutinin-induced T-lymphocyte proliferation and cytokine production were significantly enhanced. Additionally, although mature human cells have not been thought to enter the murine thymus, human T lymphocytes were detected in the huPBL-NOD-SCID thymus after rhIL-15 treatment. Thus, rhIL-15 can be used to optimize long-term peripheral T-cell engraftment in these human-mouse chimeras and may also be useful in clinical treatment of T-cell deficiencies.


arrow
INTRODUCTION
 
The NOD/LtSz-prkdcscid/prkdcscid (nonobese diabetic-severe combined immune deficiency [NOD-SCID]) mouse has provided a useful model with which to examine normal human immune function and development in vivo (12, 14). NOD-SCID mice lack functional lymphoid cells and show little or no serum immunoglobulin (Ig) with age (46). The original study by Mosier et al. reported that human lymphocytes could be engrafted into SCID mice (30). In human peripheral blood lymphocyte (huPBL)-SCID/NOD-SCID chimeric mice, human T and B cells persisted for months and could be detected in the peritonea and peripheral lymphoid organs. The chimeras were capable of mounting antigen-specific secondary responses to various antigens after immunization (13, 28, 29, 32, 34-36).

However, a limitation of the huPBL-SCID/NOD-SCID model is the low level of huPBL engraftment (31, 47). This problem has made the analysis of antigen-specific cellular immune responses extremely difficult and limited the usage of this model in-depth studies. Various strategies have been explored to improve the efficiency of huPBL engraftment into huPBL-SCID/NOD-SCID mice, including an increase in the number of cells transferred (15, 30), pretreatment of the recipient mice with low-dose irradiation (1, 37, 45), or elimination of mouse natural killer (NK) cells by anti-asialo-GM1 (2, 37, 45) or a combination of irradiation and anti-asialo-GM1 (4). All these protocols have shown only marginal effects if both the functions and distributions of transferred lymphocytes in lymphoid organs or tissues of huPBL-SCID/NOD-SCID mice were considered.

Regarding the efficiency of engraftment of huPBLs into SCID/NOD-SCID mice, a wide variety of stimulators of human hematopoiesis have also been tested in efforts to promote the engraftment of lymphocytes into huPBL-SCID/NOD-SCID mice; these stimulators include interleukin 6 (IL-6), IL-4, growth hormone, and chemokines (6, 10, 33, 48). IL-15 was originally isolated from culture supernatants of the simian kidney epithelial cell line CV-1/EBNA (11) and has been shown to have hematopoiesis-promoting effects, including development and differentiation of natural killer (NK) cells, proliferation of T cells, and maturation of B cells (7, 11, 22, 25, 42). A 4-day treatment with IL-15 in serum-free medium alone or synergically with IL-2 enhanced the cytotoxicity of human NK and LAK cells against tumor cells (23, 24). It was also found that IL-15 improved stem cell development in a semisolid colony assay system (7). Those observations indicate that IL-15 is a strong immune hematopoiesis-promoting cytokine that may be an appropriate candidate for promoting transplantation of huPBLs into NOD-SCID mice. In this study, we have found that recombinant human IL-15 (rhIL-15) can be used for reconstitution of human T cells in NOD-SCID mice.


arrow
MATERIALS AND METHODS
 
Mice. NOD/LtSz-prkdcscid/prkdcscid mice were obtained from the Animal Production Area (Shanghai laboratory animal center, Chinese Academy of Sciences). Mice were not used until the age of 8 to 12 weeks. NOD-SCID mice were housed in microisolator cages, with all sterile food, water, and bedding. NOD-SCID mice received trimethoprim and sulfamethoxazole (40 mg/ml trimethoprim and 200 mg sulfamethoxazole per 320 ml water) in their drinking water and were kept under specific-pathogen-free conditions at all times.

Creation of huPBL-NOD-SCID mice. All donors for huPBLs were from the Anhui Provincial Blood Bank, were routinely screened for human immunodeficiency virus and hepatitis B virus, and provided informed consent before donation. The huPBLs were separated by Ficoll (Sigma, St Louis, MO) density gradient centrifugation following lysis of the red blood cells. The recovered cells usually were found to contain more than 90% lymphocytes when examined by lymphocyte counting. The mice received total-body irradiation at 3.0 Gy, followed by injection of 5 x 107 freshly isolated huPBLs intraperitoneally (i.p.) within 2 to 4 h after irradiation.

Mice were then injected i.p. with either the indicated amount of rhIL-15 (Immunex, Seattle, WA) or Hanks' balanced salt solutions (HBSS) as a control every other day for a total of 10 injections, starting on day 1. The protocol for rhIL-15 or HBSS treatment and the point for the appropriate analysis are diagramed in Fig. 1.


Figure 1
View larger version (15K):
[in this window]
[in a new window]
  		FIG. 1. Protocol for examination of engraftment of huPBLs into NOD-SCID mice. huPBLs were separated by Ficoll density gradient centrifugation and washed twice with HBSS. After the cells were counted and adjusted to 1 x 108/ml, 5 x 107/0.5 ml of the purified huPBLs were transferred i.p. into recipient NOD-SCID mice that had been pretreated with irradiation. After transfer, the huPBL-NOD-SCID mice were injected i.p. either with the indicated amount of rhIL-15 or with HBSS as a control every other day for a total of 10 injections starting on day 1.

Preparation of mononuclear cells from immune organs of huPBL-NOD-SCID mice. Under deep ether anesthesia, the mice were sacrificed by exsanguination from the subclavian artery and vein, and then the spleen, liver, lymph nodes, and thymus were removed and a femur was dissected. To obtain the mononuclear cells from peripheral lymphoid organs, the liver was pressed through a 200-gauge stainless-steel mesh and then suspended in HBSS. After incubation on ice for 20 min, the supernatant was centrifuged at 2,400 rpm for 30 min at 4°C, the cells were then resuspended in 40% Percoll (GIBCO-BRL Ltd.) solution containing 100 U/ml heparin, and the cell mixture was loaded on a layer of 70% Percoll solution and then centrifuged at 2,400 rpm for 30 min at 4°C. The interface cells between the Percoll solutions were aspirated and washed twice with HBSS. Splenocytes were passed through a 200-gauge stainless-steel mesh and were treated with erythrocyte lysis solution (155 mM NH4Cl, 10 mM KHCO3, 1 mM EDTA, and 170 mM Tris, pH 7.3). After incubation on the ice for 7 min, the lysis response was terminated with HBSS, and cells were harvested by centrifugation and then washed twice in HBSS solution before use. The cells of the lymph nodes and thymus were treated in the same way as splenocytes. Peripheral blood was collected from the orbital sinus of each mouse and suspended in HBSS containing 100 U/ml heparin. The cells were then treated with erythrocyte lysis solution as described above.

Flow cytometry analysis. Mononuclear cells of the peritoneal cavity, spleen, thymus, liver, lymph nodes (pooled from mesenteric, axillary, and inguinal lymph nodes), and peripheral blood were harvested on the indicated days after rhIL-15 or HBSS treatment of huPBL-NOD-SCID mice. These cells were prepared by gentle homogenization in ice-cold HBSS and were washed once with ice-cold HBSS as previously described (35). Mononuclear cells were stained with fluorescein isothiocyanate (FITC)-, Cy-, or phycoerythrin (PE)-conjugated anti-human marker monoclonal antibodies, including PE-labeled anti-HLA-ABC, Cy-labeled anti-CD3, FITC-labeled anti-CD19, PE-labeled anti-CD8, and FITC-labeled anti-CD4 (all the antibodies were obtained from Becton Dickinson) in phosphate-buffered saline-1% bovine serum albumin and were washed with HBSS medium. At least 104 to 105 lymphocytes, including mouse and human lymphocytes, were acquired in each run. For each mouse analyzed, cells were also stained with mouse IgG conjugated to FITC and PE as an isotype control. Fluorescence levels that excluded more than 98% of the cells in the negative controls were considered to be positive and specific for human staining. The cells were fixed in a 3% formalin-HBSS solution and stored at 4°C until flow cytometry analysis. Samples gated on the forward light scatter (FSC) and side light scatter (SSC) were used to identify viable lymphocytes. Proportions of the major subsets were determined by single and quadrant analysis. The percentage of Cy-, FITC-, or PE-positive cells was measured by a FACScan using the CELLQUEST program (Becton Dickinson, San Jose, CA).

Proliferation assay by [3H]thymidine incorporation. From day 1 to day 20 after huPBL transfer, huPBL-NOD-SCID mice were injected i.p. with rhIL-15 (1 µg/injection, given every other day for a total of 10 injections). On day 28, both the cells of lymph nodes from huPBL-NOD-SCID mice and donor huPBLs were harvested and suspended in RPMI 1640 medium containing 10% fetal calf serum in 1 x 106 human T cells/ml. The cells (1 x 105/100 µl/well) were cultured in 96-well flat-bottom plates (Costar) with or without 10 µg/ml phytohemagglutinin (PHA) (Sigma). Three days later, the proliferation activity of lymph node cells was assayed by pulsing with 1 µCi (3.7 x 104 Bq) of [3H]thymidine (6.7 Ci/mmol) (Shanghai Nuclear Technique Company of the Chinese Academy) for 8 h. The radioactivity of each sample was counted by a liquid scintillation counter (LS-6500; Beckman).

Detection of cytokines. The supernatants from the proliferation assay with PHA stimulation were collected at 18, 36, and 72 h. Then we measured the production of gamma interferon (IFN-{gamma}) and IL-2 by the supernatants by a quantitation enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's instructions (RayBiotech, Inc.).

Statistical analysis. All experiments were performed at least three times. Student's t test was performed to determine the statistical difference. A P value of <0.05 was considered significant.


arrow
RESULTS
 
IL-15 promoted the engraftment of human T cells into the thymuses and spleens of huPBL-NOD-SCID mice in a dose-dependent manner. A limitation of the huPBL-SCID/NOD-SCID model is the low level of huPBL engraftment (31, 47). Previous studies have demonstrated that rhIL-15 promotes human T-cell proliferation and activation in vitro and in vivo, showing that IL-15 has hematopoiesis-promoting actions (11, 22, 25, 42). In this study, we aimed to investigate the role of IL-15 in T-cell engraftment using the huPBL/NOD-SCID model.

The irradiated recipient NOD-SCID mice were transplanted with 5 x 107 freshly prepared huPBLs. To determine the optimal dosage of rhIL-15, the huPBL-NOD-SCID mice received different doses of rhIL-15—0.25, 0.5, 1, and 2 µg per mouse—and the control group received HBSS. The results had shown that 4 weeks after huPBL transplantation, the percentages of HLA-ABC+ CD3+ T lymphocytes prepared from the thymuses and spleens of rhIL-15-treated huPBL-NOD-SCID mice had increased in a dose-dependent manner (Fig. 2). B-cell engraftment in the spleen after IL-15 treatment was also observed. Unexpectedly, splenic HLA-ABC+ CD19+ B cells showed no significant change after rhIL-15 treatment. These results suggest that IL-15 can enhance T-cell engraftment during huPBL transplantation. In the preliminary study, when mice received 10 µg rhIL-15 each, they manifested obvious skin lesions and other serious xenogeneic graft-versus-host disease (X-GVHD) symptoms. Therefore, we selected 1 µg of rhIL-15 per mouse as the optimal dosage for subsequent experiments.


Figure 2
View larger version (40K):
[in this window]
[in a new window]
  		FIG. 2. rhIL-15 promoted the transplantation of human T cells into lymphoid organs of NOD-SCID mice in a dose-dependent manner. Recipient mice that had been pretreated with irradiation received transplants of freshly prepared huPBLs. To determine the optimal dosage of rhIL-15, the huPBL-NOD-SCID mice were then divided into five groups with five mice in each group. Four dosages of rhIL-15 in HBSS were tested in this study: 0.25, 0.5, 1, and 2 µg of rhIL-15 in 0.2 ml of HBSS per mouse, and an equal volume of HBSS was used in control groups. Mice were injected i.p. either with different dosages of rhIL-15 or with HBSS every other day for a total of 10 injections. Four weeks after the huPBL transplantation, mononuclear cells from the thymus and spleen were isolated and stained with anti-HLA-ABC, anti-CD3, and anti-CD19 and were then analyzed by flow cytometry. Data are representative of three independent experiments, with similar results obtained in each experiment. P < 0.001 for comparison between rhIL-15 groups with different dosages and the HBSS group.

IL-15 enhanced human T-lymphocyte engraftment into lymphoid organs or tissues of NOD-SCID mice. In order to further understand the engraftment-promoting effect of IL-15, we observed T-cell populations in other peripheral lymphoid organs or tissues. The results showed that IL-15 could increase the percentage of T cells not only in the thymus and the spleen but also in the liver, lymph nodes, and peripheral blood (Fig. 3A). With regard to the increase in the total number of lymphocytes in the thymus, spleen, liver, lymph nodes, and peripheral circulating blood during transplantation, the absolute number of human T cells was significantly increased about 80-fold in the thymus, 27-fold in the spleen, about 24-fold in the liver, 28-fold in the lymph nodes, and 11-fold in peripheral circulating blood in the rhIL-15-treated group (Fig. 3B). Simultaneously, the percentage and absolute number of T cells were dramatically decreased in the peritoneal cavity, suggesting that enhanced T-cell repopulation is due to the role of IL-15 in enhanced T-cell trafficking to lymphoid organs and tissues. To further address this issue, we observed the dynamics of T-cell numbers in three organs, the peritoneal cavity, the spleen, and the thymus, which had abundant T cells during the process of huPBL transplantation. As expected, T-cell numbers went up in the spleen and the thymus, along with a gradual decrease in the peritoneal cavity (Fig. 4). Taken together, rhIL-15 promoted the engraftment of human T cells into lymphoid organs or tissues of NOD-SCID mice, probably through its enhanced migration or trafficking.


Figure 3
View larger version (33K):
[in this window]
[in a new window]
  		FIG. 3. rhIL-15 accelerated human T-lymphocyte engraftment into lymphoid organs or tissues of NOD-SCID mice. One microgram of rhIL-15 in 0.2 ml of HBSS or an equal volume of HBSS as a control was injected i.p. into each huPBL-NOD-SCID mouse once. The injection scheme of rhIL-15 or HBSS is diagramed in Fig. 1. One week after the last rhIL-15 injection (on day 28), the organs or tissues, including the peritoneal cavity, thymus, spleen, liver, lymph nodes, and peripheral blood, were collected, and the mononuclear cells from the organs or tissues were isolated as described in Materials and Methods, stained with PE-labeled anti-HLA-ABC and Cy-labeled anti-CD3, and then analyzed by flow cytometry. (A) HLA-ABC+ and CD3+ percentages of the lymphoid organs or tissues from grafted mice administered HBBS and rhIL-15. Data shown are representative of three independent experiments, with similar results obtained in each experiment. P < 0.01 for comparison of the rhIL-15 group with the HBSS group. (B) HLA-ABC+ CD3+ cell populations were calculated from total-lymphoid-organ cell numbers and 1 ml peripheral blood of the mice using the proportions (percentages) of these cells. Results are expressed as means ± standard deviations for three independent assays. P < 0.001 for comparison of the rhIL-15 group with the HBSS group.


Figure 4
View larger version (38K):
[in this window]
[in a new window]
  		FIG. 4. rhIL-15 promoted the trafficking of human T cells to lymphoid organs of NOD-SCID mice. To prove the promoting role of IL-15 in T-cell trafficking to lymphoid organs and tissues, we collected the mononuclear cells from the peritoneal cavities, spleens, and thymuses of rhIL-15-treated huPBL-NOD-SCID mice on days 7, 14, 21, and 28 after huPBL transfer, stained them with PE-labeled anti-HLA-ABC and Cy-labeled anti-CD3, and then analyzed them by flow cytometry. Data are representative of three independent experiments, with similar results obtained in each experiment.

IL-15 treatment showed no difference in its effects on engraftment of CD4+ versus CD8+ cells. Next, we investigated the effect of IL-15 on engraftment of T-cell subsets. As shown in Fig. 5, CD4+ and CD8+ cells account for 49% and 25% of donor huPBLs, respectively. Twenty-eight days after transplantation, both CD4+ and CD8+ T cells had repopulated the thymus, spleen, lymph nodes, liver, and peripheral blood well in rhIL-15-treated huPBL-NOD-SCID mice. The ratios of CD4+ to CD8+ cells in these organs or tissues were equal to those in donor huPBLs before transplantation. In summary, the engraftment-promoting effects of IL-15 on the CD4+ and CD8+ T-cell subsets were similar.


Figure 5
View larger version (26K):
[in this window]
[in a new window]
  		FIG. 5. Flow cytometry analysis of human T-lymphocyte subsets from lymphoid organs or tissues of huPBL-NOD-SCID mice. To test human T-lymphocyte subsets from lymphoid organs or tissues of huPBL-NOD-SCID mice, on day 28, the lymphoid organs or tissues of huPBL-NOD-SCID mice and donor huPBLs were collected, stained with Cy-labeled anti-CD3, FITC-labeled anti-CD4, and PE-labeled anti-CD8 antibodies, and then analyzed by flow cytometry. The analysis was performed on gated lymphocytes with FSC/SSC characteristics. Results are expressed as means ± standard deviations for three independent assays. P < 0.001 for comparison of the rhIL-15 group with the HBSS group.

Human T cells isolated from IL-15-treated huPBL-NOD-SCID mice had normal function. In addition to the distribution and phenotype of engrafted huPBLs in rhIL-15-treated huPBL-NOD-SCID mice, the functional characteristics of huPBLs were also investigated. Lymphocytes were harvested from lymph nodes of huPBL-NOD-SCID mice that had been injected with rhIL-15. The human T-cell-specific mitogen response (PHA-stimulated proliferation) was tested. As shown in Fig. 6, the counts per minute increased significantly in lymphocytes from rhIL-15-treated huPBL-NOD-SCID mice after PHA stimulation. The supernatants of PHA-stimulated lymphocytes from rhIL-15-treated huPBL-NOD-SCID chimeras contained high concentrations of IFN-{gamma} and IL-2 (Fig. 7A and B). There is no statistically significant difference in T-cell proliferation and cytokine production between engrafted T cells isolated from IL-15-treated huPBL-NOD-SCID mice and human donor PBLs, suggesting that the former function normally, like freshly isolated huPBLs.


Figure 6
View larger version (13K):
[in this window]
[in a new window]
  		FIG. 6. Proliferation of the cells of lymph nodes from rhIL-15-treated huPBL-NOD-SCID chimeras stimulated with PHA in vitro. On day 28 after huPBL transfer, the cells of lymph nodes of rhIL-15-treated mice and donor huPBLs were harvested. All cells (1 x 105 human T cells/100 µl/well) were cultured in 96-well flat-bottom plates with or without 10 µg/ml PHA. Three days later, proliferation activity was assayed by pulsing with 1 µCi (3.7 x 104 Bq) of [3H]thymidine (6.7 Ci/mmol) for 8 h; the radioactivity for each sample was counted by a liquid scintillation counter. Data are presented as the means ± standard deviations of triplicate samples. There was no obvious difference between donor T cells and rhIL-15-treated chimera human T cells in response to PHA. P < 0.001 for comparison of the lymphocytes of the rhIL-15-treated chimera with and without PHA.


Figure 7
View larger version (22K):
[in this window]
[in a new window]
  		FIG. 7. Cytokine production by the cells of lymph nodes from huPBL-NOD-SCID mice treated with rhIL-15. The cells of lymph nodes from rhIL-15-treated mice and donor huPBLs were used in this experiment. The cells were cultured in 96-well flat-bottom plates with or without 10 µg/ml PHA in vitro. At 18, 36, or 72 h, as indicated, cell culture supernatants were collected for determination of IFN-{gamma} (A) or IL-2 (B) by quantitation ELISA. Data are presented as the means ± standard deviations of triplicate samples. There was no obvious difference in cytokine production between donor T cells and rhIL-15-treated chimera human T cells. P < 0.001 for comparison of the lymphocytes of the rhIL-15-treated chimera at different time points with and without PHA.


arrow
DISCUSSION
 
Reports have been accumulating from studies examining the role of IL-15 in immune function (3, 7, 9, 22-25, 42). A high-affinity receptor for IL-15 has been described on human B cells, T cells, and NK cells, and activation of these cells results in a further induction of IL-15 receptor (IL-15R) expression (3, 25). IL-15R has been shown to play a critical role in IL-2-induced T-cell proliferation in vitro (41). A defect in the IL-15R gamma chain leads to a significant loss of thymic lymphocytes in SCID mice (43). Recently, it was reported that IL-15 exhibited a dose-dependent enhancement of murine IgM and IgG secretion from B cells that were treated with anti-IgM and IL-2 or anti-IgM alone in vitro and in vivo (5, 17, 40). Furthermore, IL-15R has been found on NK cells (8, 39, 49, 51), and IL-15 was able to increase the proliferation response and cytotoxicity of NK cells against sensitive or nonsensitive tumor cells in humans, mice, and rats, either independently or synergically with IL-2 (19, 21, 50, 52-54). It is also noted that rhIL-15 improved the differentiation and engraftment of human NK cells from human hematopoietic stem cells in NOD-SCID mice (18).

Here we reported that the use of rhIL-15 could significantly improve the engraftment and reconstitution of human T lymphocytes in NOD-SCID mice after transfer of human peripheral blood mononuclear cells. Significantly larger amounts of human T lymphocytes were found in the thymuses of rhIL-15-treated mice than in those of untreated control mice. The thymus differs from other lymphoid organs because it manifests more restricted cell entry, leading to more difficult trafficking to the murine thymus due to a lack of appropriate adhesion molecules (26). These results suggested a pivotal role of IL-15 in normal T-lymphocyte development, which allowed thymus entry of human lymphocytes and promoted peripheral localization of the mature T cells from the thymus to the spleen, lymph nodes, and liver (Fig. 3). The lymphoid liver is a newly emerging concept that has been a hot spot for immunologists, and the characterization of the liver as a lymphoid organ has been discussed in several reviews (20, 27, 38). Meanwhile, we investigated the distribution of human lymphocytes in nonlymphoid organs such as the small intestine and lung; the results showed that there were no human lymphocytes in these organs in huPBL-NOD-SCID mice (data not shown). All these findings meant that there was a selective migration of huPBLs into lymphoid organs or tissues. We also showed that differences in the background numbers of human CD3+ T cells in lymphoid organs or tissues appeared to be donor dependent. Different donors generally have different background migration. This may be due to the activation state, phenotype, or adhesive ability of the donor T cells.

Reportedly, IL-15 plays a major role in maintenance of CD8+ memory T cells (16, 44), but our data showed no obvious difference in the effects of IL-15 on the engraftment of CD4+ versus CD8+ T cells into NOD-SCID mice. The differences may result from the difference in the dosage of rhIL-15 used. It is guessed that IL-15 at a high dose may preferentially promote CD8+ T-cell engraftment.

Our test also revealed that the dosage of rhIL-15 was very important to the effect on the constitution of huPBL-NOD-SCID mice. In our preliminary investigations, when mice were injected i.p. with 10 µg rhIL-15 per mouse every other day for a total of 10 times after huPBL engraftment, we found that serious X-GVHD occurred, and almost all of the mice had wasting and skin lesions and finally died. In view of severe GVHD symptoms at high doses, we chose 1 µg as a rational dose in that the effectiveness of T-cell engraftment at 1 µg was similar to that at 2 µg; moreover, mice that received 1 µg IL-15 showed no GVHD symptoms.

Moreover, when rhIL-2 was used as a positive control in the treatment of huPBL-NOD-SCID mice in our study, we found that rhIL-15 had still better abilities to promote engraftment and reconstitution of human T lymphocytes in NOD-SCID mice than rhIL-2 (data not shown), although rhIL-2 showed limited promoting activities. The proliferation of T cells and cytokines secreted by rhIL-15-treated huPBL-NOD-SCID mice was significantly enhanced and was not obviously different from that of donor human T cells when the cells were stimulated with PHA (Fig. 6 and 7), indicating that the engrafted human T lymphocytes have normal function and that this kind of model can be used in future work.

In our experiments, 1 month after adoptive transfer, human B cells were found mainly in the peritoneal cavity, but that only accounted for approximately 1 to 5% of the total cells. It is possible that these B cells migrated to lymphoid organs if they did not die in situ. Human B cells were only occasionally observed in secondary lymphoid tissues, such as the spleen and lymph nodes, in huPBL-NOD-SCID mice. Flow cytometry analysis indicated that there was no significantly greater engraftment of HLA-ABC+ CD19+ cells in lymphoid organs of rhIL-15-treated mice than in the control. However, high levels of human immunoglobulin were observed in sera of rhIL-15-treated huPBL-NOD-SCID mice, indicating that human B cells must be present and functional in these mice, though it may be difficult to define the phenotype and quantities of human B cells in the mice.

Our findings suggest that rhIL-15 has clinical applications in immune deficiency diseases or bone marrow transplantation, where it might be advantageous to accelerate peripheral expansion and to promote localization of T cells. The molecular mechanisms underlying the effects of rhIL-15 in huPBL-NOD-SCID mice are under investigation.


arrow
ACKNOWLEDGMENTS
 
This work was supported by the Outstanding Young Scientist Award and the Key Project of the Natural Science Foundation of China (grants 30125038, 30230340, 30328012, and 30371308), the Key Basic Science Program of the Ministry of Science and Technology of China (grants 2001CB510009 and 2003CB515501), and the Foundation of the Chinese Academy of Science (KSCX2-2-08).

We thank Xiaodong Zheng for managing the flow cytometry and Bin Lin and his colleagues for outstanding services.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: School of Life Sciences, University of Science and Technology of China, 443 Huangshan Road, Hefei City, Anhui 230027, China. Phone: 86-551-360-7379. Fax: 86-551-360-6783. E-mail: tzg{at}ustc.edu.cn. Back


arrow
REFERENCES
 
    1
  1. Abedi, M. R., B. Christensson, K. B. Islam, L. Hammarstrom, and C. I. E. Smith. 1992. Immunoglobulin production in severe combined immunodeficient (SCID) mice reconstituted with human peripheral blood mononuclear cells. Eur. J. Immunol. 22:823-828.[Medline]
    2. 2
  2. Albert, S. E., C. Mckerlie, A. Pester, B.-J. Edgell, J. Carlyle, M. Petric, and J. W. Chamberlain. 1997. Time-dependent induction of protective antiinfluenza immune responses in human peripheral blood lymphocyte/SCID mice. J. Immunol. 159:1393-1403.[Abstract]
    3. 3
  3. Baird, A. M., R. M. Gerstein, and L. J. Berg. 1999. The role of cytokine receptor signaling in lymphocyte development. Curr. Opin. Immunol. 11:157-166.[CrossRef][Medline]
    4. 4
  4. Barry, T. S., D. M. Jones, C. B. Richter, and B. F. Haynes. 1991. Successful engraftment of human postnatal thymus in severe combined immune deficient (SCID) mice: differential engraftment of thymic components with irradiation versus anti-asialo GM-1 immunosuppressive regimens. J. Exp. Med. 173:167-180.[Abstract/Free Full Text]
    5. 5
  5. Bernasconi, N. L., E. Traggiai, and A. Lanzavecchia. 2002. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298:2199-2202.[Abstract/Free Full Text]
    6. 6
  6. Bombil, F., D. Latinne, J. P. Kints, and H. Bazin. 1996. Human recombinant interleukin-4 (HurIL-4) improves SCID mouse reconstitution with human peripheral blood lymphocytes. Immunobiology 196:437-448.[Medline]
    7. 7
  7. Bykovskaia, S. N., M. Buffo, H. Zhang, M. Bunker, M. L. Levitt, and M. Agha. 1999. The generation of human dendritic and NK cells from hematopoietic progenitors induced by interleukin-15. J. Leukoc. Biol. 66:659-666.[Abstract]
    8. 8
  8. Carson, W. E., J. G. Giri, M. J. Lindemann, M. L. Linett, M. Ahdieh, R. Paxton, D. Anderson, J. Eisenmann, K. Grabstein, and M. A. Caligiuri. 1994. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J. Exp. Med. 180:1395-1403.[Abstract/Free Full Text]
    9. 9
  9. Chklovskaia, E., C. Nissen, L. Landmann, C. Rahner, O. Pfister, and A. Wodnar-Filipowicz. 2001. Cell-surface trafficking and release of flt3 ligand from T lymphocytes is induced by common cytokine receptor gamma-chain signaling and inhibited by cyclosporin A. Blood 97:1027-1034.[Abstract/Free Full Text]
    10. 10
  10. Coccia, M. A., S. J. Weeks, C. L. Knott, and K. Kuus-Reichel. 1998. Human IL-6 enhances human lymphocyte engraftment and activation but not human antibody production in SCIDhu PBL mice. Immunobiology 198:396-407.[Medline]
    11. 11
  11. Giri, J. G., D. M. Anderson, S. Kumaki, L. S. Park, K. H. Grabstein, and D. Cosman. 1995. IL-15, a novel T cell growth factor that shares activities and receptor components with IL-2. J. Leukoc. Biol. 57:763-766.[Abstract]
    12. 12
  12. Greiner, D. L., L. D. Shultz, J. Yates, M. C. Appel, G. Perdrizet, R. M. Hesselton, I. Schweitzer, W. G. Beamer, K. L. Shultz, and S. C. Pelsue. 1995. Improved engraftment of human spleen cells in NOD/LtSz-scid/scid mice as compared with C.B-17-scid/scid mice. Am. J. Pathol. 146:888-902.[Abstract]
    13. 13
  13. Greiner, D. L., R. A. Hesselton, and L. D. Shultz. 1998. SCID mouse models of human stem cell engraftment. Stem Cells 16:166-177.[Abstract/Free Full Text]
    14. 14
  14. Hesselton, R. M., D. L. Greiner, J. P. Mordes, T. V. Rajan, J. L. Sullivan, and L. D. Shultz. 1995. High levels of human peripheral blood mononuclear cell engraftment and enhanced susceptibility to human immunodeficiency virus type I infection in NOD/LtSz-scid/scid mice. J. Infect. Dis. 172:974-982.[Medline]
    15. 15
  15. Hoffmann-Fezer, G., C. Gall, U. Zengerle, B. Kranz, and S. Thierfelder. 1993. Immunohistology and immunocytology of human T-cell chimerism and graft-versus-host disease in SCID mice. Blood 81:3440-3448.[Abstract/Free Full Text]
    16. 16
  16. Judge, A. D., X. Zhang, H. Fujii, C. D. Surh, and J. Sprent. 2002. Interleukin 15 controls both proliferation and survival of a subset of memory-phenotype CD8+ T cells. J. Exp. Med. 196:935-946.[Abstract/Free Full Text]
    17. 17
  17. Kacani, L., G. M. Sprinzl, A. Erdei, and M. P. Dierich. 1999. Interleukin-15 enhances HIV-1-driven polyclonal B-cell response in vitro. Exp. Clin. Immunogenet. 16:162-172.[CrossRef][Medline]
    18. 18
  18. Kalberer, C. P., U. Siegler, and A. Wodnar-Filipowicz. 2003. Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD34+ cells. Blood 102:127-135.[Abstract/Free Full Text]
    19. 19
  19. Kishida, T., H. Asada, Y. Itokawa, F. D. Cui, M. Shin-Ya, and S. Gojo. 2003. Interleukin (IL)-21 and IL-15 genetic transfer synergistically augments therapeutic antitumor immunity and promotes regression of metastatic lymphoma. Mol. Ther. 8:552-558.[CrossRef][Medline]
    20. 20
  20. Kita, H., I. R. Mackay, J. Van de Water, and M. E. Gershwin. 2001. The lymphoid liver: considerations on pathways to autoimmune injury. Gastroenterology 120:1485-1501.[CrossRef][Medline]
    21. 21
  21. Klebanoff, C. A., S. E. Finkelstein, D. R. Surman, M. K. Lichtman, L. Gattinoni, and M. R. Theoret. 2004. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc. Natl. Acad. Sci. USA 101:1969-1974.[Abstract/Free Full Text]
    22. 22
  22. Kondo, M., and I. L. Weissman. 2000. Function of cytokines in lymphocyte development. Curr. Top. Microbiol. Immunol. 251:59-65.[Medline]
    23. 23
  23. Kozar, K., R. Kaminski, A. Giermasz, G. Basak, R. Zagozdzon, and J. Rybczynska. 2002. IL-12 or IL-15, unlike IL-2, does not interact with histamine in augmenting cytotoxicity of splenocytes against melanoma cells and YAC-1 cells. Oncol. Rep. 9:427-431.[Medline]
    24. 24
  24. Leclercq, G., V. Debacker, M. de Smedt, and J. Plum. 1996. Differential effects of interleukin-15 and interleukin-2 on differentiation of bipotential T/natural killer progenitor cells. J. Exp. Med. 184:325-336.[Abstract/Free Full Text]
    25. 25
  25. Lodolce, J. P., D. L. Boone, S. Chai, R. E. Swain, T. Dassopoulos, S. Trettin, and A. Ma. 1998. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 9:669-676.[CrossRef][Medline]
    26. 26
  26. McCune, J. M., R. Namikawa, H. Kaneshima, L. D. Schultz, M. Lieberman, and I. L. Weissman. 1988. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science 241:1632-1639.[Abstract/Free Full Text]
    27. 27
  27. Mehal, W. Z., F. Azzaroli, and I. N. Crispe. 2001. Immunology of the healthy liver: old questions and new insights. Gastroenterology 120:250-260.[Medline]
    28. 28
  28. Mosier, D. E. 1996. Human immunodeficiency virus infection of human cells transplanted to severe combined immuno-deficient mice. Adv. Immunol. 63:79-125.[Medline]
    29. 29
  29. Mosier, D. E. 1996. Viral pathogenesis in hu-PBL-SCID mice. Semin. Immunol. 8:255-262.[CrossRef][Medline]
    30. 30
  30. Mosier, D. E., R. J. Gulizia, S. M. Baird, and D. B. Wilson. 1988. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 335:256-259.[CrossRef][Medline]
    31. 31
  31. Mosier, D. E., R. J. Gulizia, S. M. Baird, and D. B. Wilson. 1989. On the SCIDs? Nature 338:211.[Medline]
    32. 32
  32. Murphy, W. J., S. K. Durum, M. R. Anver, and D. L. Longo. 1992. Immunological and haematological effects of neuroendocrine hormone: studies on DW/J. dwarf mice. J. Immunol. 148:3799-3808.[Abstract]
    33. 33
  33. Murphy, W. J., S. K. Durum, M. Anver, M. Frazier, and D. L. Longo. 1992. Recombinant human growth hormone promotes human lymphocyte engraftment in immunodeficient mice and results in an increased incidence of human Epstein Barr virus-induced B-cell lymphoma. Brain Behav. Immun. 6:355-364.[CrossRef][Medline]
    34. 34
  34. Murphy, W. J., D. D. Taub, and D. L. Longo. 1996. The huPBL-SCID mouse as a means to examine human immune function in vivo. Semin. Immunol. 8:233-241.[CrossRef][Medline]
    35. 35
  35. Murphy, W. J., Z. G. Tian, O. Asai, S. Funakoshi, P. Rotter, and M. Henry. 1996. Chemokines and T lymphocyte activation. II. Facilitation of human T cell trafficking in severe combined immunodeficiency mice. J. Immunol. 156:2104-2111.[Abstract]
    36. 36
  36. Murphy, W. J., S. Funakoshi, W. C. Fanslow, H. C. Rager, D. D. Taub, and D. L. Longo. 1999. CD40 stimulation promotes human secondary immunoglobulin responses in HuPBL-SCID chimeras. Clin. Immunol. 90:22-27.[CrossRef][Medline]
    37. 37
  37. Nonoyama, S., F. O. Smith, and H. D. Ochs. 1993. Specific antibody production to a recall or a neoantigen by SCID mice reconstituted with human peripheral blood lymphocytes. J. Immunol. 151:3894-3901.[Abstract]
    38. 38
  38. Norris, S., C. Collins, D. G. Doherty, F. Smith, G. McEntee, O. Traynor, N. Nolan, J. Hegarty, and C. O'Farrelly. 1998. Resident human hepatic lymphocytes are phenotypically different from circulating lymphocytes. J. Hepatol. 28:84-90.[Medline]
    39. 39
  39. Ohteki, T., S. Ho, H. Suzuki, T. W. Mak, and P. S. Ohashi. 1997. Role for IL-15/IL-15 receptor ß-chain in natural killer 1.1+ T cell receptor-{alpha}ß+ cell development. J. Immunol. 159:5931-5935.[Abstract]
    40. 40
  40. Orengo, A. M., E. Di Carlo, A. Comes, M. Fabbi, T. Piazza, M. Cilli, P. Musiani, and S. Ferrini. 2003. Tumor cells engineered with IL-12 and IL-15 genes induce protective antibody responses in nude mice. J. Immunol. 171:569-575.[Abstract/Free Full Text]
    41. 41
  41. Perera, L. P., C. K. Goldman, and T. A. Waldmann. 1999. IL-15 induces the expression of chemokines and their receptors in T lymphocytes. J. Immunol. 162:2606-2612.[Abstract/Free Full Text]
    42. 42
  42. Pierelli, L., G. Scambia, G. Bonanno, A. Coscarella, R. De Santis, and A. Mele. 1999. Expansion of granulocyte colony-stimulating factor/chemotherapy-mobilized CD34+ hematopoietic progenitors: role of granulocyte-macrophage colony-stimulating factor/erythropoietin hybrid protein (MEN11303) and interleukin-15. Exp. Hematol. 27:416-424.[CrossRef][Medline]
    43. 43
  43. Plum, J., M. De Smedt, G. Leclercq, B. Verhasselt, and B. Vandekerckhove. 1996. Interleukin-7 is a critical growth factor in early human T-cell development. Blood 88:4239-4245.[Abstract/Free Full Text]
    44. 44
  44. Roychowdhury, S., B. W. Blaser, A. G. Freud, K. Katz, D. Bhatt, A. K. Ferketich, V. Bergdall, D. Kusewitt, R. A. Baiocchi, and M. A. Caligiuri. 2005. IL-15 but not IL-2 rapidly induces lethal xenogeneic graft-versus-host disease. Blood 106:2433-2435.[Abstract/Free Full Text]
    45. 45
  45. Shpitz, B., C. A. Chambers, A. B. Singhal, N. Hozumi, B. J. Fernandes, C. M. Roifman, L. M. Weiner, J. C. Roder, and S. Gallinger. 1994. High level functional engraftment of severe combined immunodeficient mice with human peripheral blood lymphocytes following pretreatment with radiation and anti-asialo GM1. J. Immunol. Methods 169:1-15.[CrossRef][Medline]
    46. 46
  46. Shultz, L. D., P. A. Schweitzer, S. W. Christianson, B. Gott, I. B. Schweitzer, B. Tennent, S. McKenna, L. Mobraaten, T. V. Rajan, and D. J. Greiner. 1995. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J. Immunol. 154:180-191.[Abstract]
    47. 47
  47. Tary-Lehmann, M., and A. Saxon. 1992. Human mature T cells that are anergic in vivo prevail in SCID mice reconstituted with human peripheral blood. J. Exp. Med. 175:503-516.[Abstract/Free Full Text]
    48. 48
  48. Taub, D. D., M. L. Key, D. L. Longo, and W. J. Murphy. 1997. Chemokine-induced human lymphocyte infiltration and engraftment in huPBL-SCID mice. Methods Enzymol. 287:265-291.[CrossRef][Medline]
    49. 49
  49. Toomey, J. A., F. Gays, D. Foster, and C. G. Brooks. 2003. Cytokine requirements for the growth and development of mouse NK cells in vitro. J. Leukoc. Biol. 74:233-242.[Abstract/Free Full Text]
    50. 50
  50. van den Broeke, L. T., E. Daschbach, E. K. Thomas, G. Andringa, and J. A. Berzofsky. 2003. Dendritic cell-induced activation of adaptive and innate antitumor immunity. J. Immunol. 171:5842-5852.[Abstract/Free Full Text]
    51. 51
  51. Verma, S., S. E. Hiby, Y. W. Loke, and A. King. 2000. Human decidual natural killer cells express the receptor for and respond to the cytokine interleukin 15. Biol. Reprod. 62:959-968.[Abstract/Free Full Text]
    52. 52
  52. Wu, J., and L. L. Lanier. 2003. Natural killer cells and cancer. Adv. Cancer Res. 90:127-156.[CrossRef][Medline]
    53. 53
  53. Zhang, J., R. Sun, H. Wei, J. Zhang, and Z. G. Tian. 2004. Characterization of stem cell factor gene-modified human natural killer cell line, NK-92 cells: implication in NK cell-based adoptive cellular immunotherapy. Oncol. Rep. 11:1097-1106.[Medline]
    54. 54
  54. Zhang, J., R. Sun, H. Wei, J. Zhang, and Z. G. Tian. 2004. Characterization of interleukin-15 gene-modified human natural killer cells: implications for adoptive cellular immunotherapy. Haematologica 89:338-347.[Abstract/Free Full Text]

Clinical and Vaccine Immunology, February 2006, p. 227-234, Vol. 13, No. 2
1071-412X/06/$08.00+0     doi:10.1128/CVI.13.2.227-234.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sun, A.
Right arrow Articles by Tian, Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sun, A.
Right arrow Articles by Tian, Z.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»